Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Posted by Jessica Moore on Mar 15th, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.51 and traded as low as $1.20. Aytu BioPharma shares last traded at $1.20, with a volume of 21,489 shares changing hands.

Aytu BioPharma Stock Performance

The company has a current ratio of 0.98, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $7.43 million, a PE ratio of -0.83 and a beta of -1.63. The firm’s fifty day moving average price is $1.51 and its 200 day moving average price is $1.82.

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.28) earnings per share (EPS) for the quarter. Aytu BioPharma had a negative net margin of 7.62% and a negative return on equity of 19.30%.

Institutional Trading of Aytu BioPharma

A hedge fund recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC lifted its stake in Aytu BioPharma, Inc. (NASDAQ:AYTU – Free Report) by 6.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 500,958 shares of the company’s stock after acquiring an additional 28,489 shares during the period. Aytu BioPharma accounts for about 0.7% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 25th largest position. Stonepine Capital Management LLC owned approximately 8.15% of Aytu BioPharma worth $1,177,000 as of its most recent filing with the SEC. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

About Aytu BioPharma

(Get Free Report)

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.